PNAS重磅!“1美分”实现液体活检,不用测序仪也这么牛
2017/02/10
低成本基因测序给个性化医疗带来了变革,同样,低成本的芯片也会给医学诊断带来变革。斯坦福大学的研究人员开发出了成本仅需1美分的“实验室芯片”技术,能够在无标记的情况下分析细胞,还有望通过检测血液中循环肿瘤细胞来早期诊断癌症。


在2017年剑桥健康科技研究所会议,专家们曾表示基于CTCs的液体活检技术主要局限于它的成本,可开发基于微流控芯片的技术来绕开成本障碍。2月6日,斯坦福大学医学院的研究人员在PNAS上展示了低成本且可重复使用的“实验室芯片”。借助常规喷墨打印机,该技术或可实现“1美分”的液体活检:分离CTC,实现早期诊断癌症。

技术核心:两个系统


Multifunctional, inexpensive, and reusable nanoparticle-printed biochip for cell manipulation and diagnosis

所有文章仅代表作者观点,不代表本站立场。如若转载请联系原作者。
查看更多
  • Multifunctional, inexpensive, and reusable nanoparticle-printed biochip for cell manipulation and diagnosis

    Isolation and characterization of rare cells and molecules from a heterogeneous population is of critical importance in diagnosis of common lethal diseases such as malaria, tuberculosis, HIV, and cancer. For the developing world, point-of-care (POC) diagnostics design must account for limited funds, modest public health infrastructure, and low power availability. To address these challenges, here we integrate microfluidics, electronics, and inkjet printing to build an ultra–low-cost, rapid, and miniaturized lab-on-a-chip (LOC) platform. This platform can perform label-free and rapid single-cell capture, efficient cellular manipulation, rare-cell isolation, selective analytical separation of biological species, sorting, concentration, positioning, enumeration, and characterization. The miniaturized format allows for small sample and reagent volumes. By keeping the electronics separate from microfluidic chips, the former can be reused and device lifetime is extended. Perhaps most notably, the device manufacturing is significantly less expensive, time-consuming, and complex than traditional LOC platforms, requiring only an inkjet printer rather than skilled personnel and clean-room facilities. Production only takes 20 min (vs. up to weeks) and $0.01—an unprecedented cost in clinical diagnostics. The platform works based on intrinsic physical characteristics of biomolecules (e.g., size and polarizability). We demonstrate biomedical applications and verify cell viability in our platform, whose multiplexing and integration of numerous steps and external analyses enhance its application in the clinic, including by nonspecialists. Through its massive cost reduction and usability we anticipate that our platform will enable greater access to diagnostic facilities in developed countries as well as POC diagnostics in resource-poor and developing countries.

    展开 收起
发表评论 我在frontend\modules\comment\widgets\views\文件夹下面 test